How to Reconstitute MOTS-c: Bacteriostatic Water vs Sterile Water

The direct answer

Bacteriostatic water is the correct diluent whenever a MOTS-c vial will be accessed more than once, because its 0.9% benzyl alcohol preservative is generally understood to suppress bacterial growth introduced by repeated needle punctures of a multi-dose vial. Sterile water for injection contains no preservative and, under general sterile-compounding practice for preservative-free preparations, is treated as a same-use or short-interval product rather than a multi-week supply. MOTS-c itself is an investigational, mitochondria-derived peptide with no FDA-approved indication, so nothing below substitutes for a clinician's individualized guidance, and dosing figures describe research literature, not an approved regimen.

What MOTS-c is, in plain terms

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a short peptide derived from mitochondrial DNA encoding that has been investigated by researchers for its potential involvement in glucose metabolism regulation and AMPK (AMP-activated protein kinase) signaling pathways. MOTS-c is neither a branded pharmaceutical product nor currently available in an FDA-approved form, and should be distinguished from related mitochondrial peptides like humanin as well as structurally unrelated regulatory peptides involved in metabolism. As of now, no human clinical trial data demonstrating safety, efficacy, or standardized dosing protocols have been published; those seeking updated information on ongoing research efforts can consult ClinicalTrials.gov directly.

Bacteriostatic water vs sterile water: what the difference actually is

Bacteriostatic Water for Injection (BWFI) is sterile water containing 0.9% benzyl alcohol as a preservative. It is generally intended for use as a diluent for parenteral products, and its preservative is what allows a vial to be entered multiple times over a defined period rather than requiring immediate discard.

Sterile Water for Injection (SWFI) contains no antimicrobial preservative. Because there is nothing in the solution to slow bacterial growth after the vial is opened, general sterile-compounding practice treats preservative-free, single-dose preparations as intended for prompt use rather than storage over days or weeks.

A note on exact beyond-use timeframes: Some vendor and compounding-pharmacy materials cite a specific number of refrigerated days for bacteriostatic-water preparations. Because this figure depends on the base formulation, concentration, and the compounding facility's own stability testing, we are not stating a specific day count here without a facility-specific or peptide-specific stability study to support it. Ask your source (or compounding pharmacy, if applicable) for their documented beyond-use date rather than relying on a generic number.

Benzyl alcohol at the concentration used in BWFI is contraindicated for neonates because of a documented association between high cumulative benzyl alcohol exposure and a severe toxicity in premature infants. This warning applies to newborns, not to adult research use of BWFI at standard reconstitution volumes, but it is worth knowing if BWFI is ever stored where a child could access it.

Step-by-step reconstitution

Aseptic technique reduces the chance that a puncture introduces contamination into the vial. The CDC's injection safety guidance describes basic practices that apply to any parenteral preparation, including single use of needles and syringes and swabbing vial septa before each access. CDC Injection Safety

Supplies:

• MOTS-c lyophilized vial
• Bacteriostatic water for injection (or sterile water, if preparing a single dose only)
• 70% isopropyl alcohol swabs
• 29 to 31 gauge insulin syringe (0.5 mL or 1 mL)
• Sharps disposal container

Steps:

1. Wash hands thoroughly.
2. Swab the rubber septum of both vials with a fresh alcohol swab and let it dry completely before inserting a needle.
3. Draw the intended diluent volume into the syringe.
4. Insert the needle into the MOTS-c vial at an angle and release the diluent slowly along the inner glass wall rather than directly onto the powder.
5. Swirl gently until dissolved. Do not shake, vigorous agitation can physically disrupt peptide structure, which is a general property of protein/peptide handling rather than a MOTS-c-specific finding.
6. Confirm the solution is clear, with no visible particulate matter, before drawing a dose. Discard if cloudy or discolored.
7. Label the vial with the reconstitution date and concentration.
8. Refrigerate at 2 to 8°C. Do not freeze the reconstituted solution.

Working out the dose volume

Concentration errors, not diluent choice, are the most common practical mistake in peptide handling. The formula itself is simple arithmetic:

Concentration (mcg/mL) = total peptide mass (mcg) ÷ diluent volume (mL)

"Units" refers to markings on a U-100 insulin syringe (100 units = 1 mL). This table only applies to U-100 syringes; using a different syringe type without recalculating produces the wrong dose. Adding more diluent (2 mL rather than 1 mL for a 5 mg vial) lowers the concentration and increases the draw volume for a given dose, which can make small doses easier to measure precisely on a 0.5 mL syringe barrel. This is a measurement-precision tradeoff, not a difference in what the peptide does once injected.

No dosing figure in this article is a clinical recommendation. Research literature on MOTS-c has not established a standard dose, frequency, or duration for human use, and any specific number should be treated as descriptive of what has appeared in research or anecdotal protocols rather than as guidance.

Syringe and injection technique

A 29 to 31 gauge insulin syringe is standard for subcutaneous peptide injection because thinner needles generally cause less tissue trauma per injection. Use a 0.5 mL syringe when the dose volume is small, since finer graduation marks improve measurement accuracy at low volumes; reserve a 1.0 mL syringe for volumes above 0.5 mL. Confirm your specific syringe's unit markings against its packaging, since labeling conventions can differ between manufacturers.

Injection steps:

1. Swab the injection site with alcohol and let it dry.
2. Pinch a fold of skin.
3. Insert the needle at an angle appropriate to local fat thickness (leaner individuals often need a shallower angle to stay subcutaneous rather than intramuscular).
4. Inject slowly.
5. Withdraw and apply gentle pressure without rubbing.
6. Dispose of the needle immediately in a sharps container. CDC sharps disposal guidance

Rotate injection sites (abdomen, outer thigh, lateral upper arm) rather than repeatedly using the same spot. Site rotation is a well-established practice in insulin injection literature to reduce localized fat tissue changes that can affect absorption; the same general principle is reasonably extended to other subcutaneous injectables, though MOTS-c-specific absorption data at different sites has not been established.

Storage and stability

Store lyophilized (unreconstituted) MOTS-c powder frozen and protected from light, per the supplier's certificate of analysis, and avoid repeated freeze-thaw cycles of the powder before it is ever reconstituted. Once reconstituted:

• With bacteriostatic water: refrigerate at 2 to 8°C. Ask your supplier or compounding source for their specific documented beyond-use date rather than assuming a generic timeframe, since this depends on their own stability data.
• With sterile water: treat as a single preparation. Draw and use the dose promptly, and discard any remainder rather than storing it as a multi-use supply.
• Never freeze the reconstituted solution. Freezing an aqueous peptide solution can cause ice-crystal formation that physically disrupts peptide structure, a general property of protein/peptide chemistry, applicable here by extension rather than as a MOTS-c-specific published finding.

Discard any solution that looks cloudy, discolored, or contains visible particulate matter, regardless of how much time has passed since reconstitution.

Common errors worth avoiding

Wrong diluent. Plain tap water or normal saline is not a substitute for BWFI or SWFI. Saline is not formulated as a preservative-containing multi-dose diluent, and sodium chloride can interact with some peptides' electrostatic structure.

Wrong volume. Drawing the wrong diluent volume changes the concentration and therefore the dose delivered by any given syringe reading, without any visible warning sign. Recheck the concentration table above before injecting.

Contaminated technique. Touching the needle to a non-sterile surface, skipping the alcohol swab, or reusing a needle all breach basic aseptic practice described in CDC injection safety guidance. CDC Injection Safety

Improper storage. Room-temperature storage of a preservative-free or expired preparation increases contamination risk over time; the exact timeframe for bacterial growth depends on many variables and is not something this article can state as a fixed number without a specific stability study.

Sourcing and regulatory context (as of mid-2025)

MOTS-c has no FDA-approved drug application and does not appear in FDA's list of approved products. FDA Orange Book Compounded preparations produced by 503A or 503B compounding facilities are expected to follow USP <797> sterile compounding standards, but that regulatory framework governs how a preparation is compounded, it does not mean MOTS-c itself has been reviewed or approved by the FDA for any indication.

Peptides purchased from unregulated "research chemical" suppliers carry a documented history of quality problems in the broader compounded-peptide and research-chemical market, including mislabeled potency and undisclosed contents. We are not citing a specific percentage here because the exact figure attached to this claim in earlier drafts could not be verified against the source paper; readers should treat sourcing quality as a real but currently unquantified risk and prefer suppliers who provide a certificate of analysis and, where relevant, sourcing from an FDA-registered 503B outsourcing facility. Adverse events involving compounded preparations can be reported to the FDA's MedWatch program at fda.gov/safety/medwatch.

Clinician-discussion and monitoring framework

MOTS-c is investigational. If a patient or research participant is using it outside a formal trial, the conversation with a clinician should cover more than "is this safe," because the honest answer to that question is "not established." Use the checkpoints below to structure that conversation and to define when self-directed use should stop.

Before starting, disclose to a clinician:

• That MOTS-c is not FDA-approved and has no established human dosing standard.
• The exact source, formulation, and diluent being used (bacteriostatic vs sterile water), since this affects contamination risk assessment.
• Any current medications, especially anything affecting glucose metabolism, since MOTS-c research has focused on AMPK and glucose-handling pathways and a plausible-but-unproven interaction cannot be ruled out.
• Any history of benzyl alcohol sensitivity, if bacteriostatic water is the diluent.

Baseline and interval checkpoints, if use continues:

• Injection-site inspection at each use: redness, warmth, swelling, or hardening beyond mild transient irritation warrants pausing and discussing with a clinician rather than continuing on schedule.
• Periodic review of the reconstituted vial's appearance (clarity, color, particulates) before every draw, not just at the time of reconstitution.
• Any new or unexplained systemic symptom, fever, unusual fatigue, gastrointestinal symptoms, or signs of hypoglycemia if the person also uses glucose-lowering medication, should prompt discontinuation and clinical evaluation, not a "wait and see" approach, because the evidence base cannot currently rule these out as related.

Stop and seek urgent care if:

• Signs of a localized injection-site infection (spreading redness, pus, fever) appear.
• Signs of an allergic reaction (hives, facial or throat swelling, difficulty breathing) occur after injection.
• Symptoms of hypoglycemia occur in someone also taking insulin or another glucose-lowering medication.

What is the clinician's role vs. the label's role here. There is no FDA label to defer to for MOTS-c, unlike an approved drug. That means dose, frequency, and duration decisions are entirely a matter of individualized clinical judgment and informed consent about an unapproved compound, not a standard protocol that can be looked up. A clinician's job in this conversation is to weigh the specific patient's health history against an evidence base that is still preclinical or early human observational data, not to confirm a dose that has already been validated.

What is established, what is plausible, and what is not established

Established: Bacteriostatic water's preservative function and its FDA-approved role as a multi-dose parenteral diluent; sterile water's lack of preservative and its use as a single-preparation diluent; the basic arithmetic of concentration and dose volume; benzyl alcohol's contraindication in neonates; MOTS-c's lack of FDA approval as of mid-2025.

Plausible but unproven for human use: That MOTS-c meaningfully affects glucose metabolism or AMPK-related pathways in humans at research-reported doses; that exercise-induced changes in endogenous MOTS-c translate into a benefit from exogenous administration; that site-rotation and freeze-avoidance practices established for other peptides and insulin apply identically to MOTS-c specifically.

Not established: A standard human dose, frequency, or duration for MOTS-c; long-term safety data in humans; a validated beyond-use date for MOTS-c specifically reconstituted in bacteriostatic water (general USP/label information about the diluent itself is established; the peptide's own stability once dissolved has not been independently confirmed here).